DuPont de Nemours Inc vs Merck & Co., Inc. — how do they compare? DuPont de Nemours Inc trades at $144.26 (market cap $19.51B), while Merck & Co., Inc. trades at $130.24 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 16.5× DuPont de Nemours Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| DD | MRK | |
|---|---|---|
Market Cap | $19.51B | $321.77B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $131.84 |
52-Week Low | $90.24 | $77.60 |
Enterprise Value | $20.90B | $368.53B |
Dividend Yield | 1.66% | 2.61% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →